Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int GmbhfiledCriticalIvax Int Gmbh
Priority to ARP120104628priorityCriticalpatent/AR089590A1/en
Publication of AR089590A1publicationCriticalpatent/AR089590A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente se relaciona con una sal de pridopidina, una sustancia a base de fármacos que se encuentra actualmente en desarrollo para el tratamiento de la enfermedad de Huntington. Más específicamente, la presente proporciona la sal de bromhidrato aceptable farmacéuticamente. Composiciones farmacéuticas que comprenden dicha sal y usos de dicha sal como una sustancia a base de fármacos. La sal de bromhidrato de 4-(3-metanosulfonil-fenil)-1-propil-piperidina que tiene un patrón de difracción de polvo para rayos X con reflexiones que corresponden a los valores de espaciados d: 7,6; 6,9; 6,0; 5,4; 4,3; 4,2; 4,0; 3,8; 3,6; 3,1.This is related to a salt of pridopidine, a drug-based substance that is currently under development for the treatment of Huntington's disease. More specifically, the present provides the pharmaceutically acceptable hydrobromide salt. Pharmaceutical compositions comprising said salt and uses of said salt as a drug-based substance. The 4- (3-methanesulfonyl-phenyl) -1-propyl-piperidine hydrobromide salt having a powder diffraction pattern for X-rays with reflections corresponding to the d-spaced values: 7.6; 6.9; 6.0; 5.4; 4.3; 4.2; 4.0; 3.8; 3.6; 3.1.
ARP1201046282012-12-102012-12-10
PRIDOPIDINE BROMHYDRATE SALT
AR089590A1
(en)
A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.